APO Research
Talk to an analyst

APO RESEARCH · REPORT

Direct Agglutination Test

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Direct Agglutination Test Market Outlook and Growth Opportunities 2026

4 July 2026192 pages

Choose your research edition.

Industry ResearchDirect Agglutination Test Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Direct Agglutination Test Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Direct Agglutination Test Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Direct Agglutination Test Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Direct Agglutination Test Market Analysis and Forecast 2026-2032172 pages · $4,950 USD

Market perspective

The global Direct Agglutination Test market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Direct Agglutination Test is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Direct Agglutination Test is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Direct Agglutination Test is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Direct Agglutination Test market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Direct Agglutination Test market include Atlas Medical GmbH, Thermo Fisher Scientific, Bio-Rad, HiMedia, Pro Lab, Arlington Scientific, Hardy Diagnostics, Liofilchem S.r.l and Biotec, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Direct Agglutination Test market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Direct Agglutination Test and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Direct Agglutination Test revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Direct Agglutination Test market.

Direct Agglutination Test Segment by Company

Atlas Medical GmbH

Thermo Fisher Scientific

Bio-Rad

HiMedia

Pro Lab

Arlington Scientific

Hardy Diagnostics

Liofilchem S.r.l

Biotec

Direct Agglutination Test Segment by Type

Blood

Urine

Escherichia Coli

Others

Direct Agglutination Test Segment by Application

Clinics

Hospital

Other

Direct Agglutination Test Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Direct Agglutination Test status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Direct Agglutination Test key companies, revenue, market share, and recent developments.

3. To split the Direct Agglutination Test breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Direct Agglutination Test market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Direct Agglutination Test significant trends, drivers, influence factors in global and regions.

6. To analyze Direct Agglutination Test competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Agglutination Test market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Direct Agglutination Test and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Agglutination Test.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Direct Agglutination Test industry.

Chapter 3: Detailed analysis of Direct Agglutination Test company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Direct Agglutination Test in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Direct Agglutination Test in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Direct Agglutination Test Industry Trends Table 2. Direct Agglutination Test Industry Drivers Table 3. Direct Agglutination Test Industry Opportunities and Challenges Table 4. Direct Agglutination Test Industry Restraints Table 5. Global Direct Agglutination Test Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Direct Agglutination Test Revenue Share by Company (2021-2026) Table 7. Global Direct Agglutination Test Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Direct Agglutination Test Key Company Manufacturing Base & Headquarters Table 9. Global Direct Agglutination Test Company, Product Type & Application Table 10. Global Direct Agglutination Test Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Direct Agglutination Test by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Blood Table 15. Significant Companies of Urine Table 16. Significant Companies of Escherichia Coli Table 17. Significant Companies of Others Table 18. Global Direct Agglutination Test Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Direct Agglutination Test Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Direct Agglutination Test Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Direct Agglutination Test Sales Value Share by Type (2021-2026) Table 22. Global Direct Agglutination Test Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Clinics Table 24. Significant Companies of Hospital Table 25. Significant Companies of Other Table 26. Global Direct Agglutination Test Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Direct Agglutination Test Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Direct Agglutination Test Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Direct Agglutination Test Sales Value Share by Application (2021-2026) Table 30. Global Direct Agglutination Test Sales Value Share by Application (2027-2032) Table 31. Global Direct Agglutination Test Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Direct Agglutination Test Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Direct Agglutination Test Sales Value Share by Region (2021-2026) Table 34. Global Direct Agglutination Test Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Direct Agglutination Test Sales Value Share by Region (2027-2032) Table 36. Global Direct Agglutination Test Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Direct Agglutination Test Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Direct Agglutination Test Sales Value Market Share by Country (2021-2026) Table 39. Global Direct Agglutination Test Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Direct Agglutination Test Sales Value Market Share by Country (2027-2032) Table 41. Atlas Medical GmbH Company Information Table 42. Atlas Medical GmbH Business Overview Table 43. Atlas Medical GmbH Direct Agglutination Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Atlas Medical GmbH Direct Agglutination Test Product Portfolio Table 45. Atlas Medical GmbH Recent Development Table 46. Thermo Fisher Scientific Company Information Table 47. Thermo Fisher Scientific Business Overview Table 48. Thermo Fisher Scientific Direct Agglutination Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Thermo Fisher Scientific Direct Agglutination Test Product Portfolio Table 50. Thermo Fisher Scientific Recent Development Table 51. Bio-Rad Company Information Table 52. Bio-Rad Business Overview Table 53. Bio-Rad Direct Agglutination Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Bio-Rad Direct Agglutination Test Product Portfolio Table 55. Bio-Rad Recent Development Table 56. HiMedia Company Information Table 57. HiMedia Business Overview Table 58. HiMedia Direct Agglutination Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. HiMedia Direct Agglutination Test Product Portfolio Table 60. HiMedia Recent Development Table 61. Pro Lab Company Information Table 62. Pro Lab Business Overview Table 63. Pro Lab Direct Agglutination Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Pro Lab Direct Agglutination Test Product Portfolio Table 65. Pro Lab Recent Development Table 66. Arlington Scientific Company Information Table 67. Arlington Scientific Business Overview Table 68. Arlington Scientific Direct Agglutination Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Arlington Scientific Direct Agglutination Test Product Portfolio Table 70. Arlington Scientific Recent Development Table 71. Hardy Diagnostics Company Information Table 72. Hardy Diagnostics Business Overview Table 73. Hardy Diagnostics Direct Agglutination Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Hardy Diagnostics Direct Agglutination Test Product Portfolio Table 75. Hardy Diagnostics Recent Development Table 76. Liofilchem S.r.l Company Information Table 77. Liofilchem S.r.l Business Overview Table 78. Liofilchem S.r.l Direct Agglutination Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Liofilchem S.r.l Direct Agglutination Test Product Portfolio Table 80. Liofilchem S.r.l Recent Development Table 81. Biotec Company Information Table 82. Biotec Business Overview Table 83. Biotec Direct Agglutination Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Biotec Direct Agglutination Test Product Portfolio Table 85. Biotec Recent Development Table 86. Research Programs/Design for This Report Table 87. Authors List of This Report Table 88. Secondary Sources Table 89. Primary Sources List of Figures Figure 1. Direct Agglutination Test Product Image Figure 2. Global Direct Agglutination Test Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Direct Agglutination Test Market Size (2021-2032) & (US$ Million) Figure 4. Global Direct Agglutination Test Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Blood Image Figure 8. Urine Image Figure 9. Escherichia Coli Image Figure 10. Others Image Figure 11. Global Direct Agglutination Test Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Direct Agglutination Test Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Direct Agglutination Test Sales Value Share by Type (2021-2032) Figure 14. Clinics Image Figure 15. Hospital Image Figure 16. Other Image Figure 17. Global Direct Agglutination Test Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Direct Agglutination Test Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Direct Agglutination Test Sales Value Share by Application (2021-2032) Figure 20. Global Direct Agglutination Test Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Direct Agglutination Test Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Direct Agglutination Test Sales Value (2021-2032) & (US$ Million) Figure 23. North America Direct Agglutination Test Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Direct Agglutination Test Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Direct Agglutination Test Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Direct Agglutination Test Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Direct Agglutination Test Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Direct Agglutination Test Sales Value (2021-2032) & (US$ Million) Figure 29. South America Direct Agglutination Test Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Direct Agglutination Test Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Direct Agglutination Test Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Direct Agglutination Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Blood
  • Urine
  • Escherichia Coli
  • Others
Applications
  • Clinics
  • Hospital
  • Other
Companies covered
  • Atlas Medical GmbH
  • Thermo Fisher Scientific
  • Bio-Rad
  • HiMedia
  • Pro Lab
  • Arlington Scientific
  • Hardy Diagnostics
  • Liofilchem S.r.l
  • Biotec

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Direct Agglutination Test Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Direct Agglutination Test Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Direct Agglutination Test Market Dynamics
  1. 2.1 Direct Agglutination Test Industry Trends
  2. 2.2 Direct Agglutination Test Industry Drivers
  3. 2.3 Direct Agglutination Test Industry Opportunities and Challenges
  4. 2.4 Direct Agglutination Test Industry Restraints
3 Direct Agglutination Test Market by Company
  1. 3.1 Global Direct Agglutination Test Company Revenue Ranking in 2025
  2. 3.2 Global Direct Agglutination Test Revenue by Company (2021-2026)
  3. 3.3 Global Direct Agglutination Test Company Ranking (2024-2026)
  4. 3.4 Global Direct Agglutination Test Company Manufacturing Base and Headquarters
  5. 3.5 Global Direct Agglutination Test Company Product Type and Application
  6. 3.6 Global Direct Agglutination Test Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Direct Agglutination Test Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Direct Agglutination Test Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Direct Agglutination Test Market by Type
  1. 4.1 Direct Agglutination Test Type Introduction
  2. 4.1.1 Blood
  3. 4.1.2 Urine
  4. 4.1.3 Escherichia Coli
  5. 4.1.4 Others
  6. 4.2 Global Direct Agglutination Test Sales Value by Type
  7. 4.2.1 Global Direct Agglutination Test Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Direct Agglutination Test Sales Value by Type (2021-2032)
  9. 4.2.3 Global Direct Agglutination Test Sales Value Share by Type (2021-2032)
5 Direct Agglutination Test Market by Application
  1. 5.1 Direct Agglutination Test Application Introduction
  2. 5.1.1 Clinics
  3. 5.1.2 Hospital
  4. 5.1.3 Other
  5. 5.2 Global Direct Agglutination Test Sales Value by Application
  6. 5.2.1 Global Direct Agglutination Test Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Direct Agglutination Test Sales Value by Application (2021-2032)
  8. 5.2.3 Global Direct Agglutination Test Sales Value Share by Application (2021-2032)
6 Direct Agglutination Test Regional Value Analysis
  1. 6.1 Global Direct Agglutination Test Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Direct Agglutination Test Sales Value by Region (2021-2032)
  3. 6.2.1 Global Direct Agglutination Test Sales Value by Region: 2021-2026
  4. 6.2.2 Global Direct Agglutination Test Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Direct Agglutination Test Sales Value (2021-2032)
  7. 6.3.2 North America Direct Agglutination Test Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Direct Agglutination Test Sales Value (2021-2032)
  10. 6.4.2 Europe Direct Agglutination Test Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Direct Agglutination Test Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Direct Agglutination Test Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Direct Agglutination Test Sales Value (2021-2032)
  16. 6.6.2 South America Direct Agglutination Test Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Direct Agglutination Test Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Direct Agglutination Test Sales Value Share by Country, 2025 VS 2032
7 Direct Agglutination Test Country-level Value Analysis
  1. 7.1 Global Direct Agglutination Test Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Direct Agglutination Test Sales Value by Country (2021-2032)
  3. 7.2.1 Global Direct Agglutination Test Sales Value by Country (2021-2026)
  4. 7.2.2 Global Direct Agglutination Test Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Direct Agglutination Test Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Direct Agglutination Test Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Direct Agglutination Test Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Atlas Medical GmbH
  2. 8.1.1 Atlas Medical GmbH Company Information
  3. 8.1.2 Atlas Medical GmbH Business Overview
  4. 8.1.3 Atlas Medical GmbH Direct Agglutination Test Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Atlas Medical GmbH Direct Agglutination Test Product Portfolio
  6. 8.1.5 Atlas Medical GmbH Recent Developments
  7. 8.2 Thermo Fisher Scientific
  8. 8.2.1 Thermo Fisher Scientific Company Information
  9. 8.2.2 Thermo Fisher Scientific Business Overview
  10. 8.2.3 Thermo Fisher Scientific Direct Agglutination Test Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Thermo Fisher Scientific Direct Agglutination Test Product Portfolio
  12. 8.2.5 Thermo Fisher Scientific Recent Developments
  13. 8.3 Bio-Rad
  14. 8.3.1 Bio-Rad Company Information
  15. 8.3.2 Bio-Rad Business Overview
  16. 8.3.3 Bio-Rad Direct Agglutination Test Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bio-Rad Direct Agglutination Test Product Portfolio
  18. 8.3.5 Bio-Rad Recent Developments
  19. 8.4 HiMedia
  20. 8.4.1 HiMedia Company Information
  21. 8.4.2 HiMedia Business Overview
  22. 8.4.3 HiMedia Direct Agglutination Test Revenue and Gross Margin (2021-2026)
  23. 8.4.4 HiMedia Direct Agglutination Test Product Portfolio
  24. 8.4.5 HiMedia Recent Developments
  25. 8.5 Pro Lab
  26. 8.5.1 Pro Lab Company Information
  27. 8.5.2 Pro Lab Business Overview
  28. 8.5.3 Pro Lab Direct Agglutination Test Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pro Lab Direct Agglutination Test Product Portfolio
  30. 8.5.5 Pro Lab Recent Developments
  31. 8.6 Arlington Scientific
  32. 8.6.1 Arlington Scientific Company Information
  33. 8.6.2 Arlington Scientific Business Overview
  34. 8.6.3 Arlington Scientific Direct Agglutination Test Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Arlington Scientific Direct Agglutination Test Product Portfolio
  36. 8.6.5 Arlington Scientific Recent Developments
  37. 8.7 Hardy Diagnostics
  38. 8.7.1 Hardy Diagnostics Company Information
  39. 8.7.2 Hardy Diagnostics Business Overview
  40. 8.7.3 Hardy Diagnostics Direct Agglutination Test Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hardy Diagnostics Direct Agglutination Test Product Portfolio
  42. 8.7.5 Hardy Diagnostics Recent Developments
  43. 8.8 Liofilchem S.r.l
  44. 8.8.1 Liofilchem S.r.l Company Information
  45. 8.8.2 Liofilchem S.r.l Business Overview
  46. 8.8.3 Liofilchem S.r.l Direct Agglutination Test Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Liofilchem S.r.l Direct Agglutination Test Product Portfolio
  48. 8.8.5 Liofilchem S.r.l Recent Developments
  49. 8.9 Biotec
  50. 8.9.1 Biotec Company Information
  51. 8.9.2 Biotec Business Overview
  52. 8.9.3 Biotec Direct Agglutination Test Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Biotec Direct Agglutination Test Product Portfolio
  54. 8.9.5 Biotec Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst